IP Library Granted Patent US 7,331,667
Granted Patent B2
US 7,331,667 · App. 10/474,958 · Granted Feb 19, 2008

Iris pattern recognition and alignment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,331,667
App. No.
10/474,958
Granted
Feb 19, 2008
Kind
B2
Abstract

Apparatus and methods are described for aligning diagnostic and therapeutic iris images, via iris pattern recognition, for effecting more accurate laser treatment of the eye. A method for aligning a dilated pupil diagnostic iris image associated with a diagnostic measurement for calculating a laser treatment, with a constricted pupil diagnostic iris image, by identifying an iris landmark that is not identifiable solely between the two images, includes a sequential plurality of diagnostic iris images of varying pupil size such that the iris landmark can be tracked between the two images. The aligned, constricted pupil diagnostic image can then be aligned with a constricted pupil treatment image and the ablation pattern rotated accordingly. Limbal edge detection is used in the diagnostic images to provide pupil center translation information for translational alignment of the laser treatment. An improved aberrometer is disclosed having a variable visible illumination fixation target for controlling pupil size for the diagnostic images. A diagnostic and therapeutic laser eye treatment system is described incorporating the apparatus and method embodiments of the invention.

Claims (48)

1. A method for aligning a diagnostic iris image of a patient's eye having a dilated pupil with a treatment iris image of the eye having a constricted pupil, via an iris pattern recognition technique, wherein an iris recognition landmark in the dilated pupil diagnostic image is not directly identifiable with the corresponding iris recognition landmark in the constricted pupil treatment iris image, to effect an accurate laser treatment of the patient's eye that is derived from a diagnostic measurement associated with the dilated pupil, characterized by:

visibly illuminating the patient's eye with a plurality of selected levels of visible illumination to effect a corresponding plurality of different pupil sizes ranging from a constricted pupil diameter to a dilated pupil diameter;

respectively obtaining a sequential plurality of diagnostic iris images each of which has an indicia of the iris recognition landmark;

correlating the indicia of the iris recognition landmark in each sequential diagnostic iris image such that the iris recognition landmark in the constricted pupil diagnostic iris image is identifiable with the iris recognition landmark in the dilated pupil diagnostic iris image;

making a diagnostic measurement of the patient's eye and the associated diagnostic image when the pupil is dilated;

obtaining a treatment iris image of the patient's eye having a constricted pupil;

aligning the constricted diagnostic iris image with the constricted pupil treatment iris image.

2. The method of claim 1 , further characterized by adjusting the laser treatment on the eye based upon the iris alignment.

3. The method of claim 1 , wherein making the diagnostic measurement includes obtaining an indication of a wavefront aberration and an axis of astigmatism.

4. The method of claim 3 , wherein making the diagnostic measurement comprises using one of an elevation based topographer, optical raytracing, and an aberrometer.

5. The method of claim 1 , wherein the aligning comprises correlating the dilated pupil diagnostic iris image with the constricted pupil diagnostic iris image and comparing an aligned constricted pupil diagnostic iris image with the constricted pupil treatment image.

6. The method of claim 1 , wherein the aligning comprises comparing the plurality of diagnostic iris images with the treatment iris image to align the constricted pupil diagnostic iris image with the constricted pupil treatment iris image.

7. The method of claim 1 , wherein the laser treatment is directed to one of a myopia correcting ablation, a hyperopia correcting ablation, an astigmatism correcting ablation, a custom corneal ablation, a retinal ablation, and another laser eye surgery procedure.

8. The method of claim 1 , further characterized by determining an illumination independent reference landmark on the eye;

calculating a center position of the pupil with respect to the reference landmark associated with the dilated pupil diagnostic iris image;

calculating a center position of the pupil with respect to the reference landmark associated with the constricted pupil diagnostic iris image;

determining a vector displacement value for the constricted pupil center and the dilated pupil center;

adjusting the laser treatment to be performed on the constricted pupil eye with respect to the vector displacement of the dilated pupil center.

9. The method of claim 8 , wherein the illumination independent reference landmark is a portion of the limbus of the eye.

10. The method of claim 9 , wherein the portion of the limbus is a limbal edge.

11. In a diagnostic and therapeutic system for laser eye surgery wherein a diagnostic image of a patient's eye that is obtained by a diagnostic image capture is aligned with a treatment image of the patient's eye that is obtained by a treatment image capture device that is associated with a treatment laser system, via an iris pattern recognition technique, the improvement characterized by:

an illumination control device for controlling a visible illumination level on one of the patient's eye being examined and the patient's other eye, not being examined, wherein the visible illumination level acts as a control for the pupil diameter of the examined eye;

a sequential plurality of diagnostic iris images each including a different pupil diameter ranging between a dilated pupil size and a constricted pupil size corresponding to the controlled visible illumination level, wherein at least an indicia of an iris recognition landmark is identifiable in each sequential diagnostic iris image even though the corresponding iris recognition landmark is not identifiable between the constricted diagnostic pupil image and the dilated diagnostic pupil image;

an eye diagnostic measuring device for obtaining a diagnostic measurement of the patient's eye associated with the dilated diagnostic pupil image, cooperatively associated with the illumination control device and the diagnostic image capture device;

means for exporting at least one of the diagnostic iris images to the laser treatment system; and

means for aligning the dilated pupil diagnostic iris image with the constricted pupil diagnostic iris image, and further for aligning the aligned constricted pupil diagnostic iris image with the treatment iris image having a constricted pupil of a size generally corresponding to the diagnostic image constricted pupil size.

12. The system of claim 11 , wherein the means for aligning includes a treatment stage processor cooperatively engaged with the treatment image capture device.

13. The system of claim 11 , wherein the means for exporting includes at least one of a wired connection, a wireless connection, a computer file storage medium.

14. The system of claim 11 , wherein the diagnostic measurement obtained by the eye diagnostic measuring device is suitable for obtaining a wavefront information about the patient's eye.

15. The system of claim 11 , wherein the eye diagnostic measuring device includes the iris image capture device.

16. The system of claim 11 , wherein the illumination control device is separate from the diagnostic measuring device.

17. The system of claim 11 , wherein the illumination control device comprises a variable illumination fixation target and is an integrated component of the diagnostic measuring device.

18. The system of claim 11 , wherein the improvement is further characterized by a means for obtaining a vector displacement measurement between a pupil center of the dilated pupil diagnostic image and the pupil center of the constricted pupil diagnostic image.

19. The system of claim 18 , wherein the vector displacement measurement is a measurement from limbus reference position to the center of the pupil.

20. In a diagnostic and therapeutic system for laser eye surgery wherein a diagnostic image of a patient's eye that is obtained by a diagnostic image capture device that is also adapted to make a diagnostic measurement of the patient's eye, is aligned with a treatment image of the patient's eye that is obtained by a treatment image capture device which is associated with a treatment laser system, via an iris pattern recognition technique, the improvement characterized by:

an illumination control device for controlling a visible illumination level on one of the patient's eye being examined and the patient's other eye, not being examined, wherein the visible illumination level acts as a control for the pupil diameter of die examined eye;

a sequential plurality of diagnostic iris images each including a different pupil diameter ranging between a dilated pupil size and a constricted pupil size corresponding to the controlled visible illumination level, obtained by the diagnostic image capture device, wherein an iris recognition landmark is identifiable in each sequential diagnostic iris image even though the corresponding iris recognition landmark is not identifiable between the constricted diagnostic pupil image and the dilated diagnostic pupil image;

means for exporting at least one of the diagnostic iris images to the laser treatment system;

means for aligning the dilated pupil diagnostic iris image, associated with a diagnostic measurement image, with the constricted pupil diagnostic iris image; and

means for aligning the aligned constricted pupil diagnostic iris image with the treatment iris image having a constricted pupil of a size generally corresponding to the diagnostic image constricted pupil size.

21. The system of claim 20 , wherein the means for aligning the dilated pupil diagnostic iris image with the constricted pupil diagnostic iris image includes a diagnostic stage processor cooperatively engaged with the diagnostic image capture device.

22. The system of claim 21 , wherein the means for exporting includes at least one of a wired connection, a wireless connection, a computer file storage medium.

23. The system of claim 20 , wherein the diagnostic measurement obtained by the eye diagnostic measuring device is suitable for obtaining a wavefront information about the patient's eye.

24. The system of claim 20 , wherein the eye diagnostic measuring device includes the iris image capture device.

25. The system of claim 20 , wherein the illumination control device is separate from the diagnostic measuring device.

26. The system of claim 20 , wherein the illumination control device comprises a variable illumination fixation target and is an integrated component of the diagnostic measuring device.

27. The system of claim 20 , wherein the improvement is further characterized by a means for obtaining a vector displacement measurement between a pupil center of the dilated pupil diagnostic image and the pupil center of the constricted pupil diagnostic image.

28. The system of claim 21 , wherein the vector displacement measurement is a measurement from limbus reference position to the center of the pupil.

Assignments (20)
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 073637/0001 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
Reel/Frame 073654/0242 →
RELEASE OF SECURITY INTEREST Recorded Nov 20, 2025
From: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
To: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
Reel/Frame 073637/0126 →
ASSIGNMENT OF SECURITY INTEREST IN PATENTS PREVIOUSLY RECORDED AT REEL/FRAME (059913/0548) Recorded Aug 14, 2025
From: CITIBANK, N.A., AS RESIGNING AGENT
To: JPMORGAN CHASE BANK, N.A., AS SUCCESSOR AGENT
Reel/Frame 072469/0091 →
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
PATENT SECURITY AGREEMENT Recorded May 10, 2022
From: BAUSCH & LOMB INCORPORATED
To: CITIBANK, N.A. AS COLLATERAL AGENT
Reel/Frame 059913/0548 →
SECURITY AGREEMENT Recorded Feb 10, 2022
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON
Reel/Frame 059121/0001 →
SECURITY INTEREST Recorded Jun 8, 2021
From: BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH AMERICAS, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 056811/0814 →
SECURITY INTEREST Recorded Mar 11, 2019
From: BAUSCH HEALTH AMERICAS, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH HEALTH US, LLC; SOLTA MEDICAL, INC.; MEDICIS PHARMACEUTICAL CORPORATION; SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD.; SANTARUS, INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.
To: THE BANK OF NEW YORK MELLON, AS NOTES COLLATERAL AGENT
Reel/Frame 048556/0758 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: THE BANK OF NEW YORK MELLON, AS COLLATERAL AGENT
Reel/Frame 045444/0634 →
SECURITY INTEREST Recorded Feb 26, 2018
From: ATON PHARMA, INC.; BAUSCH & LOMB INCORPORATED; BAUSCH & LOMB PHARMA HOLDINGS CORP.; COMMONWEALTH LABORATORIES, LLC; DOW PHARMACEUTICAL SCIENCES, INC.; ECR PHARMACEUTICALS CO., INC.; LABORATOIRE CHAUVIN S.A.S.; MEDICIS PHARMACEUTICAL CORPORATION; ONPHARMA INC.; ORAPHARMA, INC.; PRECISION DERMATOLOGY, INC.; SALIX PHARMACEUTICALS, LTD.; SALIX PHARMACEUTICALS, INC.; SANTARUS, INC.; SOLTA MEDICAL, INC.; SYNERGETICS USA, INC.; TECHNOLAS PERFECT VISION GMBH; VALEANT CANADA LP; VALEANT PHARMACEUTICALS INTERNATIONAL; VALEANT PHARMACEUTICALS INTERNATIONAL, INC.; VALEANT PHARMACEUTICALS NORTH AMERICA LLC; WIRRA IP PTY LIMITED; VALEANT PHARMA POLAND SP. Z O.O.; VALEANT PHARMACEUTICALS LUXEMBOURG S.A R.L.; VALEANT PHARMACEUTICALS IRELAND LIMITED
To: BARCLAYS BANK PLC, AS COLLATERAL AGENT
Reel/Frame 045444/0299 →
SECURITY INTEREST Recorded Jul 19, 2017
From: BAUSCH & LOMB INCORPORATED
To: THE BANK OF NEW YORK MELLON
Reel/Frame 043251/0932 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Mar 26, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC
To: CREDIT SUISSE
Reel/Frame 020733/0765 →
CORRECTED ASSIGNMENT-ITEM 2 CO. NAME Recorded Aug 16, 2004
From: GROTESHUSMANN, ULF; YOUSEFFI, GERHARD
To: TECHNOLAS GMBH OPHTHALMOLOGISCHE SYSTEME
Reel/Frame 015062/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 22, 2004
From: GROTEHUSMANN, ULF; YOUSEFFI, GERHARD
To: BAUSCH & LOMB, INC.
Reel/Frame 014888/0375 →